Review of NICE Technology Appraisal Guidance No. 23; Temozolomide for the treatment of recurrent malignant glioma (brain cancer)

The Institute was proposing that the decision to review the guidance should be deferred to 2015.

During consultation, the majority of comments received by the Institute agreed with the proposal put forward.  After consideration of all of the comments (attached as appendix A), the Institute’s Guidance Executive has decided to proceed with the proposal. In the meantime the current guidance will be transferred to the static list of technology appraisals.

Topics on the static list may be transferred back to the active list for further appraisal if new evidence becomes available that is likely to have a material effect on the last guidance issued. 

May 2011